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Quantitative amino acid and proteomic analysis: Very low ex-
cretion of polypeptides>750 Da in normal urine.
Background. Quantitative data on protein and polypep-
tide excretion in normal urine are lacking. In Fanconi syn-
drome, failure of proximal tubular protein reabsorption leads
to ‘tubular’ proteinuria, but little is known about peptide
excretion.
Methods. Urine from normal (N = 5) and Fanconi patients
(Dent’s disease, N = 2; Lowe syndrome, N = 3) was fractionated
by size-exclusion chromatography into proteins (>10 kD) and
smaller polypeptides. Each fraction was subjected to amino acid
analysis after acid hydrolysis. In complementary proteomic ap-
proaches, urinary polypeptides were each subjected to reversed-
phase high-performance liquid chromatography (HPLC)
followed by matrix-assisted laser desorption/ionization-time-
of-flight mass spectrometry (MALDI-TOF MS) and nano-flow
liquid chromatography directly coupled to electrospray ioniza-
tion/tandem mass spectrometry (NanoLC-ESI-MS/MS) before
and after tryptic digestion.
Results. Based on amino acid composition, normal hu-
man urine, excluding Tamm-Horsfall protein, contains 33.7 ±
10.7 mg protein per 24 hr (mean ± SEM) protein defined as
polypeptide >10 kD; peptide content in range 750 Da to 10 kD
is 22.0 ± 9.6 mg. Fanconi patients excrete greatly increased
amounts of protein, 1740 ± 660 mg/24 hr, and peptide, 446 ±
145 mg/24 hr. Peptides 2 to 5 kD were present in 12.9- ± 3.9-
fold excess in Fanconi compared with normal urine. In contrast,
free amino acid excretion in Fanconi was elevated only 2.14- ±
0.73-fold. Mass spectrometric techniques determined that the
major form of albumin in both normal and Fanconi urine was
the full-length protein, and did not detect significant peptides
of nonrenal origin.
Conclusion. There is only very low excretion of polypeptides
>750 Da in normal human urine. In Fanconi syndrome, excre-
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tion of unknown peptides of mass 2 to 5 kD, possibly relevant
to the development of renal failure, is greatly increased.
Normal human urine is generally believed to be almost
free of protein and polypeptides [1–3]. This is thought to
be due to selective glomerular permeability and efficient
tubular uptake of protein filtered by the glomerulus [1].
There is much molecular, physiologic, and anatomic ev-
idence that glomerular ultrafiltration is highly selective.
Although exact measurements are not available, microp-
uncture studies in the rat suggest an albumin concentra-
tion in the glomerular filtrate of 22.9 mg/L [4], and similar
estimates have been made in the dog [5]. An indirect es-
timate in man, based on studies of the renal Fanconi syn-
drome, gave a value of approximately 3.5 ± 0.41 mg/L
[6]. Using this estimate, human plasma, which contains
some 40 g/L of albumin, forms an ultrafiltrate containing
approximately 600 mg albumin over a 24-hour period.
Over 95% of albumin is then removed from this ultra-
filtrate, probably by megalin/cubilin-dependent endocy-
tosis in the proximal tubule, to produce urine with an
albumin content of less than 30 mg/24 hr [7–9]. When this
endocytic uptake is defective, as in the Fanconi syndrome,
albumin and other proteins in the ultrafiltrate are found
in urine and constitute tubular proteinuria [10, 11].
In the Fanconi syndrome (Lignac-de Toni-Debre´-
Fanconi syndrome), reuptake of filtered proteins by the
proximal tubule is impaired, and the resulting tubular
proteinuria comprises about one half albumin, one third
low-molecular-weight proteins (retinol-binding protein,
b 2-microglobulin, and a1-microglobulin), and the re-
mainder other proteins [10, 11]. The renal Fanconi syn-
drome is found in patients with Dent’s disease (CLCN5
mutation), the oculocerebrorenal syndrome of Lowe
(Lowe syndrome), as well as cystinosis and several other
inherited and acquired diseases [10, 12, 13].
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The above description, based partly on protein mea-
surements using a variety of chromogenic total protein
assays and in-gel protein detection reagents, as well as
immunochemical estimation of individual proteins, par-
ticularly albumin, has been challenged [14]. A large body
of human and animal data from Comper et al [14] has
been interpreted to show that the normal glomerulus is
relatively leaky, and passes 100 to 600 g of plasma pro-
tein per day into the glomerular filtrate. It is believed
that a proportion of the albumin is partially degraded
and then re-excreted into the tubular lumen to produce
about 1 to 2 g of polypeptide fragments of mass 500 Da to
10 kD in the final urine. These fragments are believed to
be undetectable by chromogenic protein reagents, such
as Coomasie Blue-based dyes, as well as being unreactive
in immunoassays for the parent protein, such as albumin
[14, 15]. Correct interpretation of the available data is
critical for an understanding of both normal renal physi-
ology and for hypotheses that implicate proteinuria itself,
or peptiduria, in the progression of renal disease. This has
been a controversial issue [3, 16, 17].
In this study, we have defined proteins as polypeptides
of mass >10 kD, and use the terms polypeptide and pep-
tide interchangeably, with a definition of the mass-range
where each term is used.
A critical part of the Comper hypothesis is the inter-
pretation that chromogen formation by urine with the Bi-
uret reagent is due to polypeptides only [15]. To provide
experimental data that is more specific than the Biuret
reaction, we have re-examined protein and polypeptide
excretion in human urine in terms of its basic chemical
constituents, that is, amino acid content, following size-
exclusion chromatography (SEC) (Fig. 1). We have de-
termined conditions where there is good overall recovery
of amino acids so that no major urinary component will
be omitted.
To complement the technique of SEC and amino acid
analysis we have used a proteomic mass spectromet-
ric approach in which urinary proteins and polypep-
tides are isolated from urine and then analyzed by
mass spectrometry (MS) (Fig. 1) [18]. The MS anal-
ysis is performed either on intact polypeptides using
matrix-assisted laser desorption/ionization-time-of-flight
mass spectrometry (MALDI-TOF MS), or by analy-
sis of the tryptic digests of these polypeptides using
nano-flow liquid chromatography directly coupled
to electrospray ionization/tandem mass spectrometry
(NanoLC-ESI-MS/MS) [18]. Although the mass spectro-
metric approaches do not have the quantitative power
of amino acid analysis, they permit definitive qualitative
identification of urinary polypeptides.
As well as normal urine, we have examined Fanconi
urine. This acts as a control because protein excretion is
known to be greatly elevated and also comprises a group
of patients in which previous immunochemical studies
have shown increased excretion of several potentially
bioactive peptides, which might contribute to the pro-
gression of renal failure [6, 10, 18]
The complementary approaches of amino acid analy-
sis and mass spectrometry have produced data that are
mutually consistent, and do not support the hypothesis
that there are large quantities of polypeptide fragments
excreted in normal human urine. Furthermore, the data
suggest that even in Fanconi urine, intact proteins pre-
dominate, although there is a large increase in excretion
of polypeptides in the mass range 2 to 5 kD.
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METHODS
The flow chart shown in Figure 1 summarizes the meth-
ods used for SEC with amino acid analysis and for the
mass spectrometric experiments.
Patients and controls
Urine samples were collected as described previously
[11], and stored in liquid nitrogen until analysis. The pa-
tients with Fanconi syndrome consisted of: 2 with Dent’s
disease, patients C/II/2 with a total CLCN5 deletion,
and F/II/1, W279X [16, 19], and 3 with Lowe syndrome.
The 3 patients with Lowe’s syndrome had severe mental
and growth retardation, visual impairment, and tubular
proteinuria. The calculated creatinine clearance for the
5 patients with Fanconi syndromes was >60 mL/min
(4 patients), except for 2 Lowe syndrome patients, 33 and
37 mL/min (data not shown) [20]. The control patients
(4 male and 1 female) had no personal or family history
of renal disease, and albumin content of their urine mea-
sured immunochemically was normal (data not shown).
Preparation of urine samples
An aliquot of urine was taken for creatinine estima-
tion (Dade-Behring Dimension alkaline rate picrate
method, CREA DF33A; Dade-Behring, Deerfield, IL,
USA) and aliquots were centrifuged at 200,000g for 30
minutes at 4◦C to remove Tamm-Horsfall glycoprotein.
Size-exclusion chromatography
After ultracentrifugation, 5 mL supernatant was ap-
plied to a 40 × 2.5-cm column of Superdex 30 prep
grade agarose-dextran medium (catalog no. 17-0905-10,
Amersham Biosciences, UK, Ltd., Buckinghamshire,
UK) at 3 to 6◦C, equilibrated with 0.22 l-filtered 0.1 mol/L
ammonium bicarbonate (Fluka Brand, catalog no. 09830;
Sigma-Aldrich Co., Ltd., Dorset, UK) at a flow rate of
40 mL/h. Fractions of 4 mL were collected and frozen at
−80◦C. The column was cleaned with 0.5 mol/L sodium
hydroxide between each analysis.
Fractions that corresponded to the molecular mass
ranges shown in Figure 1 were pooled and lyophilized to
remove the volatile chromatography buffer. Finally, each
pool was redissolved in 1 to 2 mL water, split into 2 equal
portions, and relyophilized. For amino acid analysis, 1 of
these 2 samples was redissolved in 0.5 to 1 mL water.
Superdex 30 columns were calibrated with 6 molecu-
lar weight markers (catalog nos. are Sigma-Aldrich unless
stated): b2-microglobulin, MW 11.6 kD (SCIPAC, Ltd.,
Kent, UK); aprotinin, catalog no. A4529, 6.5 kD; insulin
B chain, catalog no. I6383, 3.5 kD; gastrin 1, catalog no.
G9020, 2.1 kD; substance P, catalog no. S6883, 1.62 kD,
and Asp-Asp-Asp-Asp, catalog no. A4440, 478 Da.
In preliminary experiments, columns of either
Toyopearl HW-40F (Sigma-Aldrich Co., Ltd.) 40 × 2.5
cm, or Sephadex G-10 (Amersham Biosciences, UK,
Ltd.) 80 × 1.6 cm, substituted for the Superdex 30 col-
umn, but other conditions were the same.
Trypsin digestion of albumin
Human albumin, Sigma A8763, 2 mg in 2 mL 0.1 mol/L
ammonium bicarbonate, was incubated with 100-lg
bovine trypsin, Sigma HPLC grade, T8658, for 36 hours
at 37◦C, and the reaction terminated by addition of
excess 4-(2-aminoethyl)benzenesulfonyl fluoride, Cal-
biochem catalog no. 101500. The solution was applied to a
Superdex 30 column as above, and amino acid analy-
sis performed on peptide fractions in the same way. In
preliminary experiments measuring immunoreactive al-
bumin, these conditions gave complete digestion by the
trypsin.
Amino acid analysis after acid hydrolysis
An appropriate volume of each sample and of L-
norleucine internal standard was transferred to a 4-cm ×
3-mm microtube, previously cleaned by heating to 500◦C
for 15 hours, and concentrated to dryness. Gas phase
acid (hydrochloric) hydrolysis was performed at 115◦C
for 22 hours. After removing traces of acid, the residue
was dissolved in sodium citrate loading buffer (pH 2.2),
and filtered by centrifugation through a 0.2-l filter. An
aliquot of the filtrate was injected into a loading capsule
placed in a Pharmacia Alpha Plus series amino acid ana-
lyzer (Biochrom Ltd., Cambridge, UK), and chromatog-
raphy performed on a sodium system ion exchange resin
eluting with buffers over the pH range 3.2 to 6.45. Peak
detection was achieved by mixing the eluate with ninhy-
drin at 135◦C and measuring the absorbance at 570 and
440 nm.
Physiologic amino acid analysis without acid hydrolysis
L-norleucine internal standard was added to the
pooled fractions corresponding to free amino acids and
lyophilized. This was redissolved in 100 lL water, 100
lL 10% sulphosalicylic acid was added, and the solu-
tion incubated for 60 minutes at 4◦C and centrifuged at
3000g for 15 minutes. The supernatant, 60 lL, was mixed
with 45 lL 0.3 mol/L lithium hydroxide, and 17.5 lL was
loaded into a capsule on a Biochrom 20 amino acid an-
alyzer (Biochrom Ltd.).
SDS gel electrophoresis and protein staining
The pellet derived by ultracentrifugation of 1.5 mL
urine was solubilized in Laemmli sample buffer as de-
scribed previously [21], except that 100 mmol/L dithio-
threitol was added to sample buffer. Samples were heated
for 4 minutes in a boiling water bath, and 10% to 20%
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Table 1. Total amino acid content (after hydrolysis) of mass fractions isolated from normal and Fanconi urine by size-exclusion chromatography
Approximate mass range >10 kD >5-10 kD >2-5 kD >0.75-2 kD 250-750 Da <250 Da
Normal urine (N = 5)
mg/24 hr ± SEM 33.7 ± 10.7 9.4 ± 5.0 3.8 ± 2.0 8.7 ± 2.1 31.3 ± 6.5 1021 ± 136
(range) (17.1–80.5) (4.8–14.2) (2.2–6.5) (4.7–11.9) (24.7–38.5) (556–1185)
Fanconi urine (N = 5)
mg/24 hr ± SEM 1740 ± 660 365 ± 87 55.5 ± 16.4 25.1 ± 11.1 40.2 ± 43.4 2740 ± 1070
(range) (305–3280) (140–718) (31.5–133) (4.50–74.1) (12.7–108) (702–3890)
Amino acid content is expressed as mg/24 hr ± S.E.M. and (range for the 5 subjects) based on a 24-hour creatinine excretion of 12.9 mmol [22].
Tris-HCl gels (Bio-Rad, Hemel Hempstead, UK) were
used to separate proteins that were detected by both sil-
ver and Coomasie Blue staining (Sigma AG-5 and B8522
used according to supplier’s instructions).
Extraction of peptides from urine by reversed phase (RP)
and strong cation exchange (SCX) chromatography
Urine was centrifuged at 3000g for 15 minutes and the
supernatant mixed with an equal volume of 5% acetoni-
trile (ACN)/0.1% trifluoroacetic acid (TFA), and injected
onto a C18 column (50 × 0.8 mm) packed with POROS
R2 20 RP (Applied Biosystems, Warrington, UK). The
column was washed with 20-column vol. 4% ACN/0.1%
TFA, and peptides eluted directly onto a POROS HS
SCX column (50 × 0.8 mm) (Applied Biosystems) us-
ing 150 lL of 80% ACN/0.1% TFA. Bound peptides
were washed with 20-column vol. 4% ACN/0.1% TFA,
eluted with 150 lL of 2 mol/L ammonium acetate in 25%
ACN/0.1% TFA, dried in a Speed Vac, redissolved in 5%
ACN/0.1% TFA, and protein quantitated by Bradford
assay.
Reversed-phase HPLC (RP-HPLC) of urine proteins
and peptides
Solvent A was 0.1% TFA, and solvent B 80%
ACN/0.1% TFA. Polypeptides (5 lg) from SCX were in-
jected onto a C18 POROS R2 10 column (250 mm ×
320 lm) eluted at 20 lL/min, and washed with the fol-
lowing% solvent B with the balance solvent A: 5% B for
8 minutes, 15% B for 1 minute, 15% to 60% B in 27 min-
utes, and finally 100% B for 20 minutes.
MALDI-TOF MS of RP-HPLC fractions
RP-HPLC fractions were dried, redissolved in
10 lL water, and 0.5 lL mixed with 1 lL of 2,5-
dihydroxybenzoic acid (DHB) on a MALDI plate, dried,
and MALDI-TOF mass spectra–collected in an Ultra-
flex TOF/TOF mass spectrometer (Bruker Daltonik,
Bremen, Germany).
NanoLC-ESI-MS/MS
Five microliters of each RP-HPLC fraction redissolved
as above was added to 10 lL of 50 mmol/L ammonium bi-
carbonate containing 100 ng of sequencing grade trypsin
(Promega, Madison, WI, USA) and incubated overnight
at 37◦C. NanoLC-ESI-MS/MS of the resultant tryptic
peptides was carried out with an Ultimate HPLC (LC
Packings, Amsterdam, The Netherlands) connected on-
line to a Q-TOF mass spectrometer (Micromass, Manch-
ester, UK).
MALDI-TOF MS of SEC fractions of ≤750 Da
SEC fractions corresponding to molecular masses
≤750 Da were pooled, lyophilized, desalted using an SPE
cartridge (Oasis; Millipore, Billerica, MA, USA), and
loaded on an SCX column equilibrated with 0.5% acetic
acid/20% CAN, and the absorbance at 280 nm allowed
to return to baseline. The eluate was collected and re-
ferred to as the acidic fraction. The mobile phase was then
changed to 500 mmol/L ammonium acetate dissolved in
0.5% acetic acid/20% CAN, and the eluate referred to as
the basic fraction. The acidic and basic fractions were an-
alyzed by MALDI-TOF MS and NanoLC-ESI-MS/MS,
as above.
Nonpeptide Biuret chromogens
A mixture of the following was made in 50 mmol/L
sodium phosphate pH 7.00: urea, 330 mmol/L (Sigma
U0631); creatinine 13.3 mmol/L (Sigma C4380); am-
monium chloride, 36 mmol/L (Merck 10017); uric acid,
3.1 mmol/L (Sigma U2875); D-glucose, 0.4 mmol/L
(Sigma G7021); L-histidine, 1 mmol/L (Sigma H8125);
L-cystine, 0.1 mmol/L (Sigma C8755); L-asparagine,
0.2 mmol/L (Sigma A0884); L-serine, 0.45 mmol/L (Sigma
S4500); L-threonine, 0.2 mmol/L (Sigma T8625); uro-
bilin, 1 mg/L (Porphyrin Products U590–9); hippuric
acid, 9 mmol/L (Sigma H6529); s -methyl-L-histidine,
0.34 mmol/L (Bachem F2480); and phenyl glucuronide,
2 mmol/L (Fluka 78555).
RESULTS
Table 1 and Figure 2 show the total amino acid con-
tent of normal and Fanconi urine in the mass range from
>10 kD (protein) to <750 Da (free amino acids or small
peptides). Amino acid content refers to amino acid con-
tent after acid hydrolysis as described in Methods, unless
stated otherwise. The complete chromatographic profile
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Fig. 2. Comparison of mean total amino acid excretion (after acid hy-
drolysis) between normal () and Fanconi () urine, mg per 24 hr in 5
mass ranges, N = 5 for each group. Bars show SEM.
of normal urine is shown in Figure 3A. To examine amino
acid content in more detail, these data are also shown in
Figure 3B, rescaled by a factor of 80 and omitting mass
<250 Da, which comprise mostly free amino acids (see
below). Figure 3B confirms the relative absence of inter-
mediate mass material. Quantities of each amino acid in
normal urine are given in Table 2.
As anticipated, Fanconi urine demonstrated gross ele-
vation of the amino acid content corresponding to mass
>10 kD (Tables 1 and 2, Figs. 2 and 4). In addition, large
increases in the excretion of smaller peptides compared
to normal urine were also found (Table 2 and Fig. 4). Al-
though the molecular mass ranges stated in Tables 1 and
2 and Figures 2 to 4 are approximate, negligible cross con-
tamination of the mass range of 2 to 5 kD with material
of >10 kD or of <750 Da was found in control exper-
iments using peptide mass standards (data not shown).
This suggests that in the Fanconi syndrome there is an
approximately 12.9-fold elevation of peptides in the 2 to
5 kD range, compared with normal urine (Table 1 and
Fig. 4).
Ultracentrifugation of urine before column chro-
matography was required to eliminate interference from
Tamm-Horsfall protein (uromodulin) and particulates.
Unless Tamm-Horsfall protein is removed from the urine,
it forms a gel barrier on the surface of the column, im-
pairing the chromatography. Ultracentrifugation caused
negligible losses of total amino acids measured after hy-
drolysis, recovery (mean ± SEM) in the supernatant fol-
lowing ultracentrifugation being 103.1 ± 5.3% and 97.5 ±
5.8% of the original normal and Fanconi urine, respec-
tively (N = 5 for each). Examination of the pellet proteins
from this step by reducing SDS gel electrophoresis and
staining with either Coomasie dye or silver showed that
the pellet contained a virtually pure protein that comi-
grated with authentic Tamm-Horsfall protein (data not
shown).
Initial experiments using the 3 size-exclusion media
as described under Methods established that only the
agarose-dextran column gave satisfactory overall recov-
ery and resolution of amino acids from urine; only this
medium was used subsequently. Overall recovery of
amino acids from urine was 73.4 ± 4.1% and 76.2 ±
12.4% for normal and Fanconi urine, respectively (N = 5
for each, defined as mean ± SEM total amino acid con-
tent after hydrolysis in all SEC fractions compared to the
quantity of amino acids applied to the column). No cor-
rection has been applied to losses due to hydrolysis (other
than any loss to the L-norleucine internal standard fol-
lowing its addition to post-chromatography fractions), or
to sample handling.
To provide further information about recovery follow-
ing SEC, the following pure proteins, of molecular weight
shown, were each applied to the agarose-dextran column
used for urine studies, and the overall recovery of pro-
tein determined and given as a percentage of that ap-
plied: b2-microglobulin, MW 11.6 kD, 90.7%; aprotinin,
6.5 kD, 69.9%; insulin B chain, 3.5 kD, 80.6%; insulin A
chain, 2.5 kD, 63.6%; gastrin 1, 2.1 kD, 75.2%; substance
P, 1.62 kD, 90.9%. Additionally, we exhaustively digested
human serum albumin with trypsin, and determined the
recovery of total amino acids following acid hydrolysis
using the same column. This gave a peptide elution pro-
file ranging from >10 kD to <750 Da (data not shown);
overall recovery of amino acids was 94%, 72% of which
comprised peptides of <10 kD.
Physiologic amino acid excretion, that is, amino acid
excretion without acid hydrolysis, was measured in
SEC fractions corresponding to free amino acids. (As
described in Methods, a different amino acid analysis
protocol was required from that used for the amino
acid analyses after acid hydrolysis described above.) Re-
sults of physiologic amino acid excretion in normal and
Fanconi urine are shown in Figure 5. In contrast to the
approximately 12.9-fold elevation of peptides in the 2 to
5 kD range in Fanconi compared to normal urine, free
amino acid excretion was only 2.14 ± 0.73-fold elevated
(N = 5 for each).
NanoLC-ESI-MS/MS of basic and acidic fractions of
the SEC fractions of molecular weight ≤750 Da did not
identify any plasma protein–derived peptides, although
peptide sequences derived from Tamm-Horsfall protein,
b-actin, and aminopeptidase N, all renal proteins, were
detected in the basic fractions (data not shown).
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Fig. 3. (A) Complete amino acid content (af-
ter hydrolysis) of mass fractions isolated from
normal urine by size-exclusion chromatogra-
phy. Results are means from the analysis of
urine specimens from 5 individuals. Amino
acids are expressed as lmol/mmol creatinine.
(B) As for (A), but omitting the fraction of
<250 Da, which contains primarily free amino
acids, and with 80-fold increase in scale. Ab-
breviations for amino acids are: G, glycine;
D+N, L-aspartic acid and L-asparagine; T, L-
threonine; S, L-serine; E+Q, L-glutamic acid
and L-glutamine; A, L-alanine; V, L-valine; M,
L-methionine; I, L-isoleucine; L, L-leucine; Y,
L-tyrosine; F, L-phenylalanine; H, L-histidine;
K, L-lysine; R, L-arginine; HO-K, hydrox-
ylysine; MeHis, 1- and 3-methyl-L-histidines;
HO-P, hydroxy-L-proline; P, L-proline.
To complement the approach based on size-exclusion
chromatography and amino acid analysis, we quantita-
tively extracted polypeptides from urine by a combina-
tion of reverse phase (RP) and Strong Cation Exchange
(SCX) chromatography. Figure 6 shows the absorbance
profile at 214 nm when equal amounts of these polypep-
tides, isolated from normal and Fanconi urine, were
subjected to RP chromatography with ultraviolet mon-
itoring and gradient elution. The isolated fractions were
examined by both MALDI-TOF MS for intact molecu-
lar weight determination, and NanoLC-ESI-MS/MS after
tryptic digestion for amino acid sequence determination.
MALDI-TOF-MS of SCX fraction 8 revealed the pres-
ence of relatively large polypeptides, including 2 m/z val-
ues that corresponded to albumin (m/z 67,800 singly, and
33,900 doubly charged), and had the same retention time
as bovine serum albumin (Fig. 7). We sequenced 33% of
albumin by NanoLC-ESI-MS/MS in fraction 8 of normal
urine (Fig. 7C), and peptides from the N-, as well as C-
termini, were detected. These data suggest that the major
form of albumin present in both Dent’s and normal urine
is the full-length protein.
Previous work by Comper et al [15] suggests that use
of the Biuret reagent as a potential peptide-bond-specific
detection reagent reveals high peptide levels in normal
urine. We investigated the specificity of this reagent un-
der the same conditions previously reported for its use
to detect protein fragments, particularly using the same
ratio of test fluid (urine) to Biuret reagent [15]. To do
this, we first screened over 50 nonpeptide compounds
known to be present in normal human urine [22] at
approximately 10-fold physiologic concentrations, and
then selected 14 compounds from these (as stated under
Methods), which gave significant absorbance at the wave-
length of the Biuret chromogen. A mixture of these com-
pounds at physiologic concentrations demonstrated an
apparent albumin-equivalent concentration of approxi-
mately 0.4 g/L. This result demonstrates a lack of speci-
ficity of the Biuret reagent under the conditions used, and
suggests that a significant proportion of apparent urinary
peptide is due to nonpeptide chromogens.
To further examine previous reports that signifi-
cant quantities of radiolabeled peptides could be sep-
arated from the urine of humans given human serum
albumin tritiated in L-lysine, we cochromatographed
radiolabeled L-lysine with different peptides, using con-
ditions on Sephadex G-100 gel filtration medium very
similar to those reported previously [23]. Although, for
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Table 2. Amino acid content (after hydrolysis)a of mass fractions isolated from normal and Fanconi urine by size-exclusion chromatography
Normal urine
Approximate mass range >10 kD >5-10 kD >2-5 kD >0.75-2 kD 250-750 Da <250 Da
Ga 1.53 ± 0.28 1.03 ± 0.12 0.42 ± 0.047 1.66 ± 0.24 2.40 ± 0.13 379 ± 47
D+N 2.42 ± 0.72 0.83 ± 0.29 0.34 ± 0.12 0.85 ± 0.10 3.74 ± 0.24 34.6 ± 2.9
T 1.66 ± 0.33 0.61 ± 0.14 0.25 ± 0.055 0.51 ± 0.074 0.68 ± 0.031 10.6 ± 1.3
S 1.72 ± 0.45 0.55 ± 0.18 0.22 ± 0.074 0.60 ± 0.08 0.88 ± 0.033 20.8 ± 1.7
E+Q 2.88 ± 0.79 0.77 ± 0.32 0.32 ± 0.13 0.80 ± 0.09 5.5 ± 0.69 119 ± 15.9
A 1.95 ± 0.72 0.52 ± 0.30 0.21 ± 0.12 0.42 ± 0.06 0.54 ± 0.03 21.1 ± 1.7
V 1.64 ± 0.55 0.38 ± 0.22 0.15 ± 0.09 0.21 ± 0.03 0.51 ± 0.03 3.4 ± 0.13
M 0.30 ± 0.087 0.079 ± 0.036 0.032 ± 0.015 <0.01 0.035 ± 0.02 0.92 ± 0.14
I 0.66 ± 0.15 0.18 ± 0.06 0.075 ± 0.025 0.033 ± 0.022 0.295 ± 0.018 1.66 ± 0.32
L 2.1 ± 0.78 0.33 ± 0.32 0.13 ± 0.13 0.12 ± 0.04 0.51 ± 0.02 2.84 ± 0.67
Y 0.89 ± 0.28 0.35 ± 0.12 0.14 ± 0.05 0.22 ± 0.08 0.67 ± 0.26 14.1 ± 0.26
F 1.15 ± 0.37 0.29 ± 0.15 0.12 ± 0.06 0.14 ± 0.13 0.27 ± 0.25 9.8 ± 0.94
H 0.60 ± 0.21 0.12 ± 0.09 0.05 ± 0.04 0.08 ± 0.01 0.09 ± 0.02 54.3 ± 5.4
K 1.5 ± 0.7 0.24 ± 0.29 0.10 ± 0.12 0.26 ± 0.03 0.72 ± 0.03 13.5 ± 1.4
R 1.0 ± 0.34 0.2 ± 0.14 0.08 ± 0.06 0.20 ± 0.03 0.11 ± 0.04 1.6 ± 0.55
HO-K <0.01 <0.01 <0.01 0.074 ± 0.02 0.075 ± 0.02 0.79 ± 0.05
MeHis <0.01 <0.01 <0.01 <0.01 0.18 ± 0.07 26.6 ± 7.8
HO-P 0.0056 ± 0.005 0.019 ± 0.002 0.008 ± 0.001 0.024 ± 0.022 0.22 ± 0.107 2.05 ± 1.1
P 1.58 ± 0.82 0.42 ± 0.34 0.17 ± 0.14 0.66 ± 0.20 1.52 ± 0.35 21.7 ± 3.6
Fanconi urine
Approximate mass range >10 kD >5-10 kD >2-5 kD >0.75-2 kD 250-750 Da <250 Da
Ga 79.4 ± 28.7 23.8 ± 7.2 7.67 ± 3.5 4.31 ± 2.49 3.68 ± 3.18 607 ± 160
D+N 116 ± 44 28.2 ± 6.2 4.17 ± 1.4 2.21 ± 1.02 4.09 ± 2.10 96.3 ± 19.6
T 71.4 ± 27.2 12.6 ± 3.0 1.88 ± 0.55 1.03 ± 0.37 1.33 ± 0.49 82.7 ± 27.5
S 74.4 ± 27.3 18.2 ± 3.9 2.64 ± 0.73 1.30 ± 0.51 1.20 ± 1.02 79.5 ± 18.0
E+Q 172 ± 68 30.8 ± 7.2 4.94 ± 1.63 2.46 ± 1.01 4.28 ± 3.07 291 ± 59
A 94.9 ± 36.5 18.6 ± 4.8 3.21 ± 1.27 1.48 ± 0.74 1.04 ± 0.75 118 ± 25
V 82.2 ± 31.6 16.9 ± 3.8 1.86 ± 0.49 0.71 ± 0.27 0.76 ± 0.45 51 ± 39
M 16.2 ± 5.9 3.16 ± 0.48 0.33 ± 0.07 0.044 ± 0.025 0.15 ± 0.03 15.4 ± 12.2
I 32.1 ± 11.6 7.80 ± 1.86 0.97 ± 0.25 0.27 ± 0.14 0.338 ± 0.385 3.6 ± 1.5
L 114 ± 45 19.0 ± 4.2 1.93 ± 0.49 0.77 ± 0.23 0.72 ± 0.67 10.1 ± 4.1
Y 42.7 ± 15.2 9.95 ± 2.29 1.34 ± 0.39 0.63 ± 0.35 0.075 ± 0.582 42.1 ± 24.4
F 56.3 ± 22.0 11.2 ± 2.6 1.31 ± 0.33 0.26 ± 0.12 1.43 ± 0.37 12.6 ± 4.1
H 29.1 ± 11.3 6.65 ± 1.55 0.90 ± 0.22 0.31 ± 0.12 0.26 ± 0.16 98.6 ± 29.0
K 91.4 ± 36.6 17.3 ± 3.9 2.43 ± 0.76 0.98 ± 0.39 1.45 ± 0.62 150 ± 46
R 58.2 ± 21.2 15.3 ± 3.6 2.04 ± 0.63 0.82 ± 0.42 0.39 ± 0.54 11.7 ± 5.9
HO-K <0.01 0.18 ± 0.13 0.099 ± 0.09 0.15 ± 0.09 2.25 ± 0.10 2.88 ± 1.19
MeHis <0.01 <0.01 <0.01 <0.01 0.168 ± 0.046 23.1 ± 9.5
HO-P 0.108 ± 0.1 0.48 ± 0.20 1.97 ± 1.01 0.93 ± 0.72 <0.01 32.4 ± 19.8
P 75.5 ± 29.6 15.8 ± 6.0 1.52 ± 0.40 0.54 ± 0.19 0.65 ± 0.58 132 ± 44
Mean ± SE expressed as lmol/mmol creatinine.
aFor abbreviations, see Figure 3 legend.
example, aprotinin (MW 6.5 kD) was eluted before free
L-lysine (MW 146 Da), an octapeptide from cholecys-
tokinin (Sigma catalog no. C2901; fragment 26–33, MW
1.06 kD) was eluted just after free L-lysine (results not
shown). This result suggests that chromatography on
Sephadex G-100 (protein size-exclusion limit 150 kD)
may give poor resolution in separating small peptides
from free amino acids.
DISCUSSION
If it could be shown that normal human urine con-
tains gram quantities of plasma protein-derived frag-
ments, much previous data on glomerular filtration and
tubular protein handling would need to be reinterpreted
[1, 3, 9]; indeed, this has been proposed [14].
We have used 2 independent experimental approaches,
size-exclusion chromatography with quantitative amino
acid analysis, and 2 mass spectrometric approaches
(Fig. 1). Both techniques have failed to detect the gram
quantities of protein fragments in normal urine predicted
by the Comper hypothesis [14]. Normal human urine,
excluding Tamm-Horsfall protein, was found to contain
33.7 ± 10.7 mg protein per 24hr (mean ± SEM), pro-
tein defined as polypeptide >10 kD, and peptide content
in the range 750 Da to 10 kD was 22.0 ± 9.6 mg. We be-
lieve this is the first report of these important nephrologic
measurements in absolute amounts. Fanconi patients ex-
creted greatly increased amounts of both protein 1740 ±
660 mg/24hr and peptide 446 ± 145 mg/24hr. Although
incomplete resolution of the 5 to 10 kD peptide frac-
tion from certain proteins is to be expected, peptides 2 to
5 kD were negligibly contaminated in this way and were
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Fig. 4. Complete amino acid content (after
hydrolysis), lmol/mmol creatinine, of mass
fractions isolated from Fanconi urine by size-
exclusion chromatography. Results are the
mean from the analysis of urine specimens
from 5 patients. Amino acids are expressed
as lmol/mmol creatinine. Abbreviations for
amino acids are as in Figure 3.
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Fig. 5. Comparison of mean physiologic amino acid excretion (no acid
hydrolysis), lmol/mmol creatinine, between normal () and Fanconi
urine (), N = 5 for each group. Bars show SEM.
elevated in 12.9 ± 3.9-fold excess in Fanconi compared
with normal urine. In contrast, free amino acid excretion
was elevated by only by 2.14 ± 0.73-fold in the 5 patients
studied with Fanconi syndromes.
Following the initial ultracentrifugation step, recovery
of total amino acid content measured after hydrolysis was
quantitative (Fig. 1 and Results); this is despite the loss of
Tamm-Horsfall protein. This good recovery is probably
explained by this protein comprising some 3% of total
urinary amino acids ([24] and Table 1) and the removal
of particulates.
We selected conditions for SEC and amino acid analy-
sis that gave good recovery of amino acids. Overall, 70%
recovery from urine was achieved without any correction
for losses, except hydrolytic losses of the L-norleucine in-
ternal standard. Purified peptides and polypeptides over
the mass range 1.62 to 11.6 kD were recovered in yields
from over 60% to 90%, and tryptic peptides from hu-
man serum albumin were recovered in an overall yield of
94%. Peptides of 750 Da or smaller were resolved from
larger peptides on the SEC system employed. Thus, it
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Fig. 6. Chromatograms of normal and Dent’s urinary polypeptides
eluted from a C18-POROS10 column. Protein (5 lg) from the urine
of (A) normal individuals () and (B) Dent’s patients () was sepa-
rated by capillary HPLC as described in Methods. Peaks marked with
an asterisk have the same retention time as bovine serum albumin. In
(C), the area under each fraction was calculated and plotted normalized
to total area. Error bars represent SEM (t test, P > 0.05, N = 3).
is highly unlikely that such plasma-derived protein frag-
ments in gram quantity could remain undetected by this
approach.
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Fig. 7. Polypeptide patterns from the ma-
jor RP-HPLC fraction in Figure 5. High
molecular weight MALDI-TOF-MS spectra
of normal (A) and Dent’s (B) fraction 8. (C)
Sequence of human serum albumin (NCBI
gene identifier 3212625). Underlined peptides
were automatically sequenced by NanoLC-
ESI-MS/MS, and correspond to 33% of the
total sequence.
The mass spectrometric approaches also failed to iden-
tify peptides in normal human urine that might be derived
from plasma proteins. Those peptides that were identified
in normal urine were probably of renal origin and had
sequences corresponding to Tamm-Horsfall protein, b-
actin, and aminopeptidase N. Most albumin peptides de-
tected probably originated from the full-length protein,
a conclusion based on gradient elution from reversed-
phase chromatography and peptide sequence data.
Furthermore, using mass spectrometric analysis of the
peptide fraction from SEC corresponding to ≤750 Da,
we were unable to detect amino acid sequences corre-
sponding to plasma proteins.
How can these results and those originating from the
Comper group be reconciled? We suggest that 2 pieces of
this group’s experimental data might need to be reinter-
preted: first, the specificity of the Biuret reaction under
the conditions used in urine studies by Greive et al [15],
and second, urine gel filtration results following the in-
travenous administration of tritiated serum albumin to
human subjects [23].
The specificity of the Biuret reaction has long been
known to be only relative [25, 26]; both keto-acids and
free amino acids are known to react with this reagent to
give the Biuret chromogen [25, 26]. This lack of specificity
is not relevant when applied to plasma, which has a pro-
tein content some 3 orders of magnitude greater than that
of normal urine. To achieve measurable absorbances with
the Biuret method applied to normal urine, the Comper
group increased the proportion of analyte volume from
less than 1.5% to 20% of the volume of the Biuret reagent.
This will also amplify any nonspecific reaction. Indeed,
using a mixture of physiologic amounts of nonpeptide
urinary constituents, we have generated significant ap-
parent peptide levels. To avoid this interference when
the Biuret reagent is used with urine, clinical chemists
have acid-precipitated urinary proteins before analysis
to remove nonpeptide chromogens [27].
Size-exclusion chromatography media permit analyte
resolution over a defined mass range. Indeed, even with
the use of an agarose-dextran gel having an exclusion
limit of approximately 10 kD, we could not always reliably
separate free amino acids from small peptides (<5-mer).
Osicka et al have presented data based on gel chromatog-
raphy in which a medium having an exclusion limit of
150 kD was used, and interpreted elution profiles in terms
of peptide fragments [23, 28]. Complete calibration data
for such chromatographic separations have not been pre-
sented. It is, as we have found here, difficult to be sure
that free amino acids and small peptides do not cochro-
matograph on SEC, or even behave anomalously with
peptide elution occurring after free amino acids. This sug-
gests a different interpretation of certain results reported
by Comper et al: it seems possible that a significant pro-
portion of the radioactivity interpreted as being due to
protein fragments may be due to free amino acid.
If there is a pathway for tubular retrieval, partial degra-
dation, and re-excretion (presumably by secretion) for
plasma proteins readily filtered at the glomerulus, it
seems curious that it is unaffected in the Fanconi syn-
drome. Our results, particularly in respect of peptide
excretion, may reflect the activity of brush-border pepti-
dases on the glomerular filtrate, as well as uptake from
the lumen. We have found patterns of protein and pep-
tide excretion in Fanconi syndromes that are fully con-
sistent with the selective filtration and efficient tubular
reuptake model. It is, however, of interest that peptides
in the range 2 to 5 kD are excreted in 12.9 ± 3.9-fold ex-
cess in Fanconi compared with normal urine. Although a
variety of peptide hormones, including insulin, has been
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previously shown to be excreted in large excess, there
probably remain many other peptides to be identified to
account for the substantial mass of peptides between 2
to 5 kD amounting to 55.5 ± 16.4 mg/24hr excreted by
Fanconi patients. Identification of such peptides might
suggest the smallest peptide structure in vivo that is pro-
cessed by the proximal tubular uptake pathway and,
therefore, by implication, megalin/cubilin-mediated en-
docytosis. In contrast to low-molecular-weight peptides,
free amino acid excretion in Fanconi was elevated only
2.14 ± 0.73-fold.
CONCLUSION
Our results are most consistent with a model in which
any polypeptides >750 Da derived from plasma proteins
are excreted in normal human urine at a level less than
that of intact proteins. The amino acid analyses and mass
spectrometric data reported here appear to be incompat-
ible with previous interpretations of human data from
use of the Biuret reaction, and of the size distribution of
radioactivity in urine following administration of radio-
labeled albumin. We suggest that this difference may be
due to lack of specificity of the Biuret reaction and over-
lapping elution of small peptides and free amino acids in
size-exclusion chromatography. In animal models, direct
experimental data based on micropuncture or tracking of
proteins labeled with fluorophores should be helpful in
further unraveling the physiologic pathway(s) of protein
handling by the renal tubule.
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